FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Signed its first global licensing deal for a blood-brain-barrier-crossing antibody platform and is developing an Alzheimer's antibody in preclinical studies. Also seen: Discovery · preclinical

  • Hyosung Ventures announced its investment, citing the February licensing deal with a global pharmaceutical company. Source

Roles often seen at this stageResearch & development · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

IMNEWRUN

A Suwon-based biotech founded in April 2019 that develops brain-disease treatments with TRANSMAB, its blood-brain-barrier-crossing antibody platform.

TRANSMAB

Technology platform

Blood-brain-barrier-crossing antibody platform; reported to have been licensed to a global pharmaceutical company under a joint R&D and licensing agreement in February 2026.

INR301

Stage unconfirmed

Preclinical antibody candidate for Alzheimer's disease that targets PD-L1 in the brain to restore immune balance.

Progress reported

Ran its first new funding round in five years, with Intervest as anchor investor.

Official role guide

IMNEWRUN careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 5

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. IMNEWRUN ↗아임뉴런 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  2. '치매 극복' 아임뉴런, 5년 만에 신규펀딩…'프리밸류 5000억' ↗팜이데일리 · Published 2026-06-19 · Sources checked 2026-11-18 · Original unavailable
  3. Hyosung Ventures Invests in AI-Based Drug Platform "I'mNeuroon" ↗The Asia Business Daily · Published 2026-05-13 · Sources checked 2026-11-18 · Original unavailable
  4. Pipeline ↗아임뉴런 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  5. Careers ↗아임뉴런 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable